Why the study?
What are the pharmacological properties and side effect profiles of penbutolol and carteolol compared to other beta-blockers in the treatment of systemic hypertension?
What are the pharmacological properties and side effect profiles of penbutolol and carteolol compared to other beta-blockers in the treatment of systemic hypertension?
Penbutolol and carteolol are long-acting, nonselective beta-blockers with partial agonist activity that offer favorable side effect profiles, including less resting bradycardia and neutral effects on lipids, for the treatment of systemic hypertension.
May guide beta-blocker selection to minimize bradycardia without lipid effects in hypertension; leaves open outcome trials versus modern agents.
Penbutolol and carteolol are two new long acting, nonselective beta-adrenergic blockers which have been approved for the treatment of systemic hypertension. Both drugs have intrinsic sympathomimetic activity (partial agonist activity), however, less than that seen with pindolol. They appear to cause less resting bradycardia than propranolol, have no effect on lipids and lipoproteins, and have favorable side effect profiles.
No takes yet. Share an insight, caveat, or question.
Frishman et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: